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Abstract
Purpose: To evaluate molecular and immunohistochem-
ical markers to develop a molecular grading of urothe-
lial bladder cancer and to test these markers in voided
urine samples.
Experimental Design: 255 consecutive biopsies from pri-
mary bladder cancer patients were evaluated on a tissue
microarray. The clinical parameters gender, age, adjacent
carcinoma in situ, and multifocality were collected. Uro-
Vysion fluorescence in situ hybridization (FISH) was
done. Expression of cytokeratin 20, MIB1, and TP53
was analyzed by immunohistochemistry. Fibroblast
growth factor receptor 3 (FGFR3) status was studied by
SNaPshot mutation detection. Results were correlated
with clinical outcome by Cox regression analysis. To as-
sess the predictive power of different predictor subsets to
detect high grade and tumor invasion, logistic regression
models were learned. Additionally, voided urine sam-
ples of 119 patients were investigated. After cytologic ex-
amination, urine samples were matched with their
biopsies and analyzed for loss of heterozygosity (LOH),
FGFR3mutation, polysomy, and p16 deletion using Uro-
Vysion FISH. Receiver operator characteristic curves for
various predictor subsets were plotted.
Results: In biopsies, high grade and solid growth pat-
tern were independent prognostic factors for overall
survival. A model consisting of UroVysion FISH and
FGFR3 status (FISH + FGFR3) predicted high grade sig-
nificantly better compared with a recently proposed
molecular grade (MIB1 + FGFR3). In voided urine, the
combination of cytology with LOH analysis (CYTO +
LOH) reached the highest diagnostic accuracy for the
detection of bladder cancer cells and performed better
than cytology alone (sensitivity of 88.2% and specificity
of 97.1%).
Conclusions: The combination of cytology with LOH
analysis could reduce unpleasant cystoscopies for blad-
der cancer patients. (Cancer Epidemiol Biomarkers Prev
2009;18(6):OF1–9)
Introduction
At the time of first diagnosis, ∼70% of bladder tumors are
noninvasive papillary low-grade tumors (pTa). Despite
the fact that the majority of urothelial bladder tumors
are clinically benign, regular cystoscopic follow-up at in-
tervals is done in all patients with non-muscle-invasive
bladder cancer after complete transurethral resection to
detect recurrence and progression.
Mutations of the tumor suppressor genes TP53 and
RB1 are common and have predictive value in clinical
studies of invasive bladder cancer (1-3). Although TP53
alterations have been suggested as prognostic marker in
pTa tumors (4), the prognostic value of both TP53 and RB1
is restricted to invasive tumors. In non-muscle-invasive
bladder cancer, homogeneous expression of cytokeratin
20 (CK20; ref. 5), lack of fibroblast growth factor receptor 3
(FGFR3) mutations (6, 7), and high nuclear Ki-67 labeling
index (7) show promise in predicting recurrence. Muta-
tions in the FGFR3 gene are very frequent in pTa bladder
tumors (∼75%; refs. 7-10). Hernandez et al. have deter-
mined the frequency and the prognostic value of FGFR3
mutations in patients with primary non-muscle-invasive
bladder cancer in a large prospective study (n = 772; ref.
11). In analogy to the data presented by van Rhijn et al.
(6), their findings strongly support the notion that FGFR3
mutations characterize a subgroup of bladder cancers
with good prognosis. However, there is no prospectively
evaluated set of molecular markers with sufficient predic-
tive power to select patients for a differential therapeutic
approach.
Conventional urine cytology is used as a complement
to cystoscopy for the detection of new bladder carcinomas
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and recurrences. However, application of cystoscopy ev-
ery 3 to 6 months is very unpleasant for the patient. In the
past, the low sensitivity of urine cytology reported in di-
agnosing low-grade papillary tumors has limited its use
and prevented cytology from replacing cystoscopy (12).
Fluorescence in situ hybridization (FISH)-based detection
systems are currently used in conjunction with cystosco-
py for the examination of bladder washings and voided
urine samples. The use of UroVysion Multicolor FISH
(Vysis), a FISH assay for detection of bladder cancer,
based on the use of voided urine samples, has been eval-
uated in multiple studies (13-15). The UroVysion FISH
test was the first and only test approved by the U.S. Food
and Drug Administration, which uses DNA probes to
identify aneuploidy for chromosomes 3, 7, and 17 and
loss of the 9p21 locus in urine specimens from subjects
with urothelial bladder cancer. van Rhijn et al. (16) have
systematically reviewed urine markers for bladder cancer
surveillance. Urinary cytology afforded a median sensi-
tivity of 35% (range, 13-75%), whereas the median sensi-
tivity for FISH and microsatellite analysis was 79%
(range, 70-86) and 82% (range, 75-92%). Microsatellite
analysis of loss of heterozygosity (LOH) and FISH were
among the most promising markers for surveillance
(16). We and others have previously shown that the detec-
tion of bladder carcinoma cells can be improved by stan-
dardized microsatellite analysis (17, 18). Over 93% of
patients with recurrent bladder cancer disease were iden-
tified by a combination of microsatellite (LOH) analyses
and cytology of their voided urine samples.
High histologic grade as a marker for chromosomal in-
stability is the clinically most important marker for in-
creased risk of progression to muscle-invasive disease.
However, histologic grading has a high interobserver var-
iability with varying prognostic implications (19).
The aim of the current study was to systematically
evaluate a set of molecular and immunohistochemical
markers to (a) develop a reliable molecular grading of ur-
othelial bladder cancer and (b) evaluate the usefulness of
these markers to detect bladder cancer cells in voided
urine.
Materials and Methods
Bladder Cancer Tissue Microarray. A tissue microar-
ray was constructed as described previously (10) from
255 consecutive, formalin-fixed, paraffin-embedded, pri-
mary urothelial bladder cancer tissues (Institute of Pathol-
ogy, University of Regensburg). Clinical data were
obtained from the Central Tumour Registry Regensburg
and by telephone interviews (M.B. and S.D.) in case of
missing data. The tissue microarray contained two tissue
cores of each tumor specimen. The Institutional Review
Board of the University of Regensburg approved analysis
of tissues from human subjects. H&E-stained slides of all
tumors were evaluated by a single surgical pathologist
(A.H.). Tumor stage and grade were assigned according
to International Union Against Cancer and WHO criteria
(20). Invasive bladder carcinomas were graded as either
low grade (G2) or high grade (G3). Growth pattern was
determined for all invasive tumors (≥pT1). Papillary
growth was defined by the presence of a papillary tumor
component (≥20%) with a histologic grade identical to the
invasive tumor. All other tumors were considered to have
a solid growth pattern. Clinicopathologic data are sum-
marized in Supplementary Table S1. Retrospective clinical
follow-up data were available regarding the endpoints
recurrence-free and overall survival. The median follow-up
period was 77 months (range, 0-166 months). Thirty-eight
Table 1. Polysomy and relative p16 deletion in relation to clinicopathologic, molecular, and immunohistochemical
markers
Variable Categorization Polysomy Relative p16 deletion
≤18% >18% P* ≤14% >14% P*
Clinicopathologic data
Tumor stage pTa 62 75 <0.001 90 47 <0.001
pT1 5 39 17 27
pT2 4 46 20 30
pT3 0 2 0 2
pT4 0 3 1 2
Histologic grade Low 64 76 <0.001 93 47 <0.001
High 7 89 35 61
Adjacent carcinoma in situ No 69 139 0.004 116 92 0.228
Yes 2 26 12 16
Multifocality Solitary 12 39 0.302 16 35 <0.001
Multifocal 59 126 112 73
Growth pattern Papillary 69 124 <0.001 114 79 0.003
Solid 2 40 14 28
Molecular data
FGFR3 gene Wild-type 12 88 <0.001 46 54 0.014
Mutation 44 49 60 33
Immunohistochemistry
MIB1 immunohistochemistry ≤25% 62 100 <0.001 94 68 0.056
>25% 7 57 28 36
TP53 immunohistochemistry ≤10% 64 103 <0.001 101 66 0.002
>10% 4 59 23 40
CK20 immunohistochemistry Superficial staining pattern 22 25 0.013 35 12 0.002
Negative or >10% 49 134 90 93
*Boldface representing P values < 0.05.
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of 215 (15%) analyzable patients died during follow-up. The
median follow-up for censored patients was 84 months. Re-
currences were defined as cystoscopically visible tumors
(using photodynamic diagnosis with 5-aminolevulinic
acid) with histologic verification.
Urine Samples. As described previously (17), voided
urine samples of 119 patients scheduled for transurethral
resection were prospectively collected over a period of 20
months and matched with their corresponding biopsies.
Of these, 81 biopsies proved to be neoplastic on histologic
examination. Characteristics are given in Supplementary
Table S2. Additional 38 urine samples were collected from
patients whose biopsies turned out to be histologically
normal or displayed inflamed urothelium without pres-
ence of neoplastic cells. Half of these tumor-negative sam-
ples were derived from patients without previous history
of bladder cancer. All urine samples (15 mL) were directly
collected at the Department of Urology, University Hospi-
tal Zurich, shortly before transurethral resection. The
urine samples were centrifuged at 1,300 × g for 10 min
and sediments were immediately processed for cytologic
examination and FISH analysis. This study has been ap-
proved by the local ethics committee (StV-14/2003; July
30, 2003) and informed consent was obtained from all
patients.
Cytologic Examination of Urine Sediments. Urine se-
diments were resuspended in PBS and one to three cytos-
pin slides were prepared from an aliquot. The slides were
fixed with Cytostat 400 solution (Simat) and stained with
standard Papanicolaou. A cell density between 25 and 50
cells per visual field using a ×20 objective was regarded as
sufficient for analysis. Slides were reviewed in a blinded
fashion by a cytopathologist (B.P.) and classified accord-
ing to the following morphologic criteria: cells with severe
atypia diagnostic of neoplasia (P), moderately atypical
cells suspicious of neoplasia (S), cells with reactive altera-
tions (NR), and cells with normal morphology (N).
Immunohistochemistry. Immunohistochemical studies
were done as described previously (10) One surgical pa-
thologist (A.H.) performed a blinded evaluation of the
slides. Positive TP53 immunoreactivity was defined as
strong nuclear staining in >10% of the tumor cells. The
percentage of MIB1-positive cells of each specimen was
determined as described previously (21). High MIB1 la-
beling index was defined if >25% of the tumor cells were
positive (7). CK20 staining was defined as normal (super-
ficial staining pattern) or abnormal (negative or >10%
stained) according to Harnden et al. (5).
DNA Isolation. Genomic DNA of paraffin-embedded
tumors on the tissue microarray was isolated from 1.5 mm
punch biopsies of the paraffin blocks (one tissue core per
case). Tumor areas were marked by a surgical pathologist
(A.H.) to ensure a tumor cell content of at least 80%. DNA
isolation was done using the Magna Pure DNA isolation
kit (Roche) according to the manufacturer's instructions.
DNA from urine samples was extracted and purified
with a DNA Blood Mini-Kit (Qiagen) following instruc-
tions of the manufacturer. For the few samples containing
only little DNA, at least 2 ng DNA was applied.
FGFR3 Mutation Analysis. FGFR3 mutation analysis
was done using the SNaPshot method (22). All mutations
were verified by a second and independent SNaPshot
analysis.
Table 2. Univariate analyses of factors possibly influencing recurrence-free and overall survival
Variable Categorization Tumor recurrence Overall survival
n* Events P† n* Events P†
Pathologic data
Tumor stage pTa 146 72 0.7534 146 4 <0.0001
pT1 48 18 48 3
pT2 56 15 56 27
pT3 2 1 2 2
pT4 3 0 3 2
Histologic grade Low 150 49 0.176 150 5 <0.0001
High 105 32 105 33
Adjacent carcinoma in situ No 222 95 0.6429 222 26 0.0001
Yes 33 11 33 12
Multifocality Unifocal tumor 53 19 0.7129 53 14 0.0029
Multifocal tumor 202 87 202 24
Growth pattern Papillary 207 95 0.3254 207 13 <0.0001
Solid 47 10 47 24
Immunohistochemistry
MIB1 ≤25% 168 76 0.7484 168 13 <0.0001
>25% 68 23 68 24
TP53 ≤10% 179 80 0.5483 179 22 0.0161
>10% 66 22 66 16
CK20 Superficial staining pattern 49 23 0.6535 49 2 0.0155
Negative or >10% 192 74 192 35
Molecular data
FGFR3 mutational status Wild-type 110 38 0.1382 110 24 0.0026
Mutation 98 50 98 7
Relative p16 deletion ≤14% 128 56 0.881 128 12 0.009
>14% 108 40 108 22
Polysomy ≤18% 71 31 0.958 71 3 0.004
>18% 165 65 165 31
*Only the initial biopsy of each patient is included.
†Log-rank test (two-sided); boldface representing P values < 0.05.
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FISH Analysis of Paraffin Specimens. Multicolor
FISH was done using the UroVysion probe set (Abbott
Laboratories) according to the manufacturer's instructions
to assess aberrations of chromosomes 3, 7, and 17 by cen-
tromeric probes and to detect relative deletions of p16 on
locus 9p21 (23). For each case, 50 nuclei were selected for
scoring according to morphologic criteria using 4′,6-
diamidino-2-phenylindole staining. Only nonoverlapping
intact nuclei were scored. Clearly distinguishable nonur-
othelial cells were disregarded. All hybridizations were
evaluated by two investigators (R.S. and I.S.) with ran-
dom quality control checks (A.H.). Each cell was simulta-
neously analyzed for centromeric signals of chromosomes
3, 7, and 17 and the p16 locus on 9p21. A cell was consid-
ered aberrant if at least one of three centromeric signals
was amplified (>2 signals per cell) or if 9p21 was deleted.
Polyploid cells (4 signals of all the three probes) were
regarded normal (euploid). A relative deletion of the
p16 locus (CDKN2A) was recognized if the signal number
of 9p21 was >1 unit lower than the mean value of the
centromeric signals. Based on the occurrence of polysomy
and deletions of 9p21 in non-tumor-associated bladder
urothelium of patients with benign prostatic hyperplasia
(n = 10), a cutoff was defined using three times the SD
(23). Accordingly, a case was considered aberrant if >9
cells of 50 showed polysomy (>18% of the cells). A sam-
ple was considered carrying a deletion of p16 if >7 of
50 cells (>14% of the cells) showed a relative deletion
of 9p21.
FISH Analysis of Voided Urine Samples. In each case,
25 selected cells were analyzed. The cell selection criteria
included patchy and lighter nuclear 4′,6-diamidino-2-phe-
nylindole staining, nuclear enlargement, irregular nuclear
contour, and presence in a small cluster. Overlapping cells
were not analyzed. Samples were scored as FISH positive,
if ≥4 cells showed at least 3 copies of any of the centro-
meric signals for chromosomes 3, 7, and 17 and if ≥12
cells displayed a homozygous loss of 9p21 (17). Due to
technical reasons, only 2 of the 38 (5%) nonneoplastic
urine samples were analyzable with FISH.
Statistical Analysis. Statistical analyses were complet-
ed using SPSS version 16.0 (SPSS) and R (24). Differences
were considered significant if P < 0.05. All samples were
considered independent.
Associations between measured parameters were ob-
tained by applying χ2 and two-sided Fisher's exact tests.
The Kaplan-Meier method was used to compare curves
for the different variables with regard to recurrence-free
and overall survival, with significance evaluated by two-
sided log-rank statistics. For the analysis of recurrence-free
survival, patients were censored at the date when cystect-
omywas done or at the time of their last tumor-free clinical
follow-up appointment. For survival analysis, patients
were censored at the time of their last clinical follow-up
appointment. Cox proportional hazard ratios were esti-
mated to obtain risks of death and to find independent
prognostic factors in a multivariate model. Limit for re-
verse selection procedures was P = 0.1.
To assess the predictive power of different predictor
subsets, a logistic regression model was learned for each
set. Cross-validation was used to validate the predictive
power of the models. Therefore, 70% of the samples were
drawn at random to form the training set on which a
model was learned, which then was tested on the 30%
of bag samples. This procedure was repeated 100 times
for each model to get estimates for the prediction error.
Student's t test was employed to quantify differences be-
tween the error distributions of different models. Data
from voided urine samples were described by plotting re-
ceiver operator characteristic (ROC) curves of the posteri-
or probability for various predictor subsets. The best
operation point was highlighted and the corresponding
sensitivity, specificity, and positive and negative predic-
tive values (PV+, PV-) were reported.
Table 3. Multivariate analysis of factors possibly influencing overall survival (n = 186)
Variable Categorization Global P Reverse selection (limit P = 0.1)
Hazard ratio (95% confidence interval) P
Pathologic data
Tumor stage pTa 0 0.558 —
pT1-4 1
Histologic grade Low 0 0.199 6.608 (1.929-22.633) 0.003
High 1
Adjacent carcinoma in situ No 0 0.516 —
Yes 1
Multifocality Unifocal tumor 0 0.304 —
Multifocal tumor 1
Growth pattern Papillary 0 0.002* 4.804 (1.959-11.783) 0.001
Solid 1
MIB1 immunohistochemistry ≤25% 0 0.823 —
>25% 1
TP53 immunohistochemistry ≤10% 0 0.106 0.488 (0.213-1.114) 0.088
>10% 1
FGFR3 gene Wild-type 0 0.199 —
Mutation 1
CK20 immunohistochemistry Superficial staining pattern 0 0.585 —
Negative or >10% 1
Relative p16 deletion ≤14% 0 0.945 —
>14% 1
Polysomy ≤18% 0 0.918 —
>18% 1
*Boldface representing P values < 0.05.
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Results
Tissue Microarray Study of Urinary Bladder Cancer.
Immunohistochemical and Molecular Markers. The prog-
nostic effect of the UroVysion kit in concert with four pre-
viously described molecular markers (FGFR3, CK20,
MIB1, and TP53) was investigated retrospectively. Inves-
tigation of UroVysion FISH in a series of 255 primary ur-
othelial bladder cancers using tissue microarray
technology was informative in 92.5% (236 of 255) of the
cases. Cases of noninterpretable results were due to poor
technical quality or lack of epithelial cell content. Polys-
omy of at least one chromosome was found in 69.9%
(165 of 236) and a relative deletion of 9p21 in 45.8%
Figure 1. A to D, analysis of the prediction performance of the three models based on noninvasive predictors (CLINICAL, FISH,
and FISH + FGFR3) and the two models based on invasive predictors (molecular grade and immunohistochemistry). The box plots
show the area under the ROC curve to predict high histologic grade (A and B) and infiltrative growth (stage ≥pT1; C and D) based on
100 cross-validation experiments. Corresponding ROC curves for the three models based on noninvasive predictors (CLINICAL,
FISH, and FISH + FGFR3) and the two models based on invasive predictors (molecular grade and immunohistochemistry). The
ROC curves plotted are generated by varying the threshold of the logistic regression model log(p(x)/(1-p(x))) = b_0+sum_{i = 1}
^{k}b_k*x_k and are the average curves based on 100 cross-validation experiments.
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(108 of 236) of urothelial neoplasms. Results of FGFR3
mutation analysis and MIB1, TP53, and CK20 immuno-
histochemistry have been published previously (10) and
are given in Supplementary Tables 1 and 3.
Table 1 shows the association of UroVysion FISH re-
sults with clinicopathologic, immunohistochemical, and
molecular parameters. Polysomy and relative p16 deletion
was significantly associated with high tumor stage, high
grade, and solid growth pattern. Almost all cases with ad-
jacent carcinoma in situ showed polysomy in at least one
chromosome (P = 0.004). These data confirm that polys-
omy and relative p16 deletions are associated with ad-
verse histopathologic characteristics. Interestingly, a
relative p16 deletion was predominantly found in solitary
compared with multifocal urothelial bladder tumors (P <
0.001). As expected, polysomy and relative p16 deletion
were significantly associated with wild-type FGFR3 sta-
tus, high proliferation, high TP53 immunoreactivity, and
abnormal CK20 staining pattern (Table 1).
Molecular and Immunohistochemical Markers and Disease
Course. The end points in the retrospective tissue microar-
ray study were recurrence-free and overall survival.
Patients with bladder tumors showing relative p16 dele-
tion or polysomy had a significantly shorter overall sur-
vival. Table 2 shows univariate P values for all variables
investigated. None of the parameters showed prognostic
effect for tumor recurrence.
We investigated the association between the molecular
markers and overall survival more closely by adjusting a
Cox regression model (Table 3). In the global model (in-
cluding tumor stage, grade, adjacent carcinoma in situ,
multifocality, growth pattern, FGFR3 status, MIB1 immu-
nohistochemistry, TP53 immunohistochemistry, CK20
staining pattern, polysomy, and relative p16 deletion),
only solid growth pattern proved to be an independent
predictor of shorter overall survival (P = 0.002). After
stepwise reverse selection (limit P = 0.1), histologic grade,
growth pattern, and TP53 immunohistochemistry re-
mained in the model. The estimated probability of death
was at least six times higher in patients with high-grade
bladder cancer than that in patients with low-grade can-
cers (P = 0.003).
Assuming different model constructs, the following
conclusions can be drawn: (a) histologic grade (high ver-
sus low grade) and growth pattern (solid versus papil-
lary) are independent prognostic factors for overall
survival and (b) relative p16 deletion and polysomy can-
not be considered independent prognostic factors for the
survival probability of bladder cancer patients.
Model Comparison. Given the prognostic effect of his-
tologic grade, sensitivity and specificity for the detection
of high-grade tumors were calculated. In this study, we
compared five different models for their power to predict
the surrogate markers high grade and infiltrative tumor
growth (stage ≥pT1) using a logistic regression model.
The first model consisted of the clinical parameters sex,
age, adjacent carcinoma in situ, and multifocality (CLIN-
ICAL). The second model comprised polysomy and rela-
tive p16 deletion (FISH). The third model extends the
FISH model for the FGFR3 mutational status (FISH +
FGFR3). The latter two models were constructed with
markers, which could also be measured noninvasively us-
ing urine. The fourth model was the molecular grading
model from van Rhijn et al. (7) and consisted of MIB1
immunohistochemistry and FGFR3 mutational status
(molecular grade). The last model consisted of the immu-
nohistochemical markers MIB1, TP53, and the CK20
pattern.
Targeting high tumor grade, the (noninvasive) FISH +
FGFR3 model performs slightly better (P = 0.001) than the
molecular grading model from van Rhijn et al. (7) with
respect to the area under curve (AUC). Both have an
AUC of ∼0.9 as shown in Fig. 1A and B. Observing the
ROC curves in Fig. 1B in detail, it can be seen that on av-
erage FISH + FGFR3 is more sensitive and that van Rhijn
et al. molecular grading is more specific regarding high
grade. The classic immunohistochemical markers were
superior to FISH + FGFR3 (P < 0.001) and the molecular
grade (P < 0.001). The clinical markers alone (CLINICAL)
perform worse than all other discussed models. FISH
analysis alone failed only in 4 of 96 high-grade bladder
cancer cases (3 pT1 and 1 pT2 tumor). All other high-grade
tumors were FISH positive.
Targeting infiltrative tumor growth (stage ≥pT1), the
FISH + FGFR3 model and the molecular grading model
performed equally well with respect to the AUC (0.9;
Fig. 1C and D). Again, classic immunohistochemistry
markers are superior to FISH + FGFR3 and the molecular
grade.
Our results show that a model consisting of UroVysion
FISH and FGFR3 status (FISH + FGFR3) can predict high
Table 4. FGFR3 analysis of voided urine samples in relation to histology, cytology, and molecular analyses
Variable Categorization FGFR3 analysis
Wild-type Mutation P*
Cystoscopically obtained biopsies
Histologic diagnosis Nonmalignant 33 1 0.005
Malignant 51 17
Voided urine samples
Cytologic diagnosis Negative cytology (N) 35 0 <0.001
Atypical cytology, not specified (NR) 20 4
Atypical cytology, suspicious (S) 12 6
Positive cytology (P) 17 8
LOH No LOH 45 4 0.032
Suspected LOH 5 1
LOH 34 13
UroVysion FISH No polysomy or loss of p16 11 2 0.290
Polysomy or loss of p16 20 10
*Fisher's exact test, two-sided; boldface representing P values < 0.05.
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grade just as well as the molecular grade proposed by van
Rhijn et al. (7) and feature a higher sensitivity. Although a
model based on the classic immunohistochemical markers
is still the most powerful regarding the target high tumor
grade, our FISH + FGFR3 model reaches nearly the same
accuracy (0.9 versus 0.95 AUC) only with markers that
could be measured with noninvasive techniques using
urine samples instead of paraffin-embedded specimens.
Parameters and P values of the FISH + FGFR3 logistic re-
gression model are given in Supplementary Table S4. The
model contained polysomy, relative p16 deletion, and
FGFR3 mutational status as predictors from which polys-
omy and FGFR3 status are significant for the prediction of
high grade.
Voided Urine Study. An independent set of 119 void-
ed urine samples were investigated to estimate the diag-
nostic power of the different assays. After cytologic
examination, voided urine samples were matched with
corresponding biopsies and analyzed for LOH, FGFR3
mutation, polysomy, and relative p16 deletion using Ur-
oVysion FISH. A mutated FGFR3 gene was found signif-
icantly more frequent in patients with malignant disease
(P = 0.005; Table 4). Only one patient with a normal
biopsy was found to have a urine specimen with mutat-
ed FGFR3. Of note is that the same patient developed a
pTa G2 bladder tumor with mutated FGFR3 within the
same year of follow-up. Mutated FGFR3 was significant-
ly associated with a positive cytologic result (P < 0.001;
Table 4). None of the cytologically negative cases dis-
played a FGFR3 mutation. Separate results of the analy-
sis of voided urine samples for patients with high-grade
(n = 40) and low-grade (n = 41) bladder tumors are giv-
en in Supplementary Table S5.
Sensitivity, specificity, and positive and negative pre-
dictive values for the detection of bladder cancer cells
in voided urine were calculated (Fig. 2A-F). Six different
models were investigated for their power to predict
bladder cancer cells in urine. The three methods (CYTO,
LOH, and FGFR3) were tested individually (Fig. 2A-C).
Additionally, FGFR3 and LOH analysis were tested in
combination with cytology (CYTO + FGFR3, and CYTO +
LOH). Targeting neoplastic cells, the combination of cy-
tology with LOH and FGFR3 analysis performed equally
well, respectively. Observing the ROC curves in Fig. 2D
and E in detail, it can be seen that on average CYTO +
FGFR3 is slightly more sensitive and CYTO + LOH is
more specific for the detection of bladder cancer cells.
Figure 2. A to F, ROC curves for six different models to predict bladder cancer cells in a set of prospectively collected voided urine
samples. The three methods (CYTO, LOH, and FGFR3) were tested individually for their ability to detect bladder cancer cells in
urine (A-C). Additionally, FGFR3 and LOH analysis were tested in combination with cytology (D and E). The combination of the
three techniques (CYTO + LOH + FGFR3) did not add significant diagnostic advantage (F).
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The combination of the three techniques (CYTO + LOH
+ FGFR3) did not add significant diagnostic advantage
(Fig. 2F) when compared with the dual models. Results
of the FISH assay could not be included in the logistic
regression analysis for cancer cell detection because only
2 of the 38 (5%) nonneoplastic urine samples were an-
alyzable with FISH. Sixty-nine percent of the urine sam-
ples from patients with a malignant bladder biopsy
were UroVysion FISH positive. Measures of the perfor-
mance of the various assays for the detection of high-
grade versus non-high-grade tumors are provided in
Supplementary Fig. S1A to F.
Discussion
In this study, we show that the combination of classic cy-
tology with LOH analysis reaches the highest diagnostic
accuracy for the detection of urothelial bladder cancer
cells in voided urine samples.
To analyze large numbers of bladder cancer specimens,
we first evaluated a tissue microarray comprising 255
consecutive, primary bladder cancers. In our survey, solid
growth pattern and high histologic grade were the most
important prognostic factor for overall survival. Howev-
er, histologic grading has a high interobserver variability
with varying prognostic implications (19). Burger et al.
(25) have shown that the current WHO classification
(20) reflects the outcome of bladder cancer patients more
accurately than the 1973 classification system (26). The
authors concluded that novel methods including molecu-
lar markers need to be evaluated for clinical use. In a sec-
ond study on urothelial bladder cancer from the same
group (n = 221), Burger et al. (25) prospectively investigat-
ed the prognostic value of the WHO 1973 and 2004 grad-
ing systems and biomarkers FGFR3, CK20, and Ki-67.
They found that both grading systems contribute valu-
able independent information. Interestingly, combining
WHO2004 gradingwith FGFR3 status allowed a better risk
stratification for patients with high-grade non-muscle-
invasive urothelial bladder cancer.
A set of molecular and immunohistochemical markers
was evaluated to develop a reliable and objective grading
systems of urothelial bladder cancer. A model consisting
of UroVysion FISH and FGFR3 status (FISH + FGFR3)
predicted high grade significantly better compared with
the molecular grade proposed by van Rhijn et al. (ref. 7;
Fig. 1A and B).
In general, urethrocystoscopy (every 3-4 months for the
first 2 years and longer intervals in subsequent years) re-
mains the standard of care for the detection and follow-up
of urothelial bladder cancer. Interestingly, van der Aa
et al. (27) have assessed the discomfort and pain reported
during follow-up of patients (n = 220) with non-muscle-
invasive low-grade urothelial bladder cancer comparing
urethrocystoscopy and surveillance by microsatellite anal-
ysis. According to van der Aa et al., periodic urethrocys-
toscopy caused pain and discomfort in about a third of
patients, whereas the burden of microsatellite analysis ap-
peared fully attributable to the waiting time for the test
result. The authors concluded that less invasive surveil-
lance tests are urgently needed (27).
But can the results of our aforementioned tissue micro-
array study be used for the detection of neoplastic cells in
voided urine? To address this question, we estimated the
diagnostic power for the detection of bladder cancer cells
in 119 voided urine samples using LOH and FGFR3 anal-
ysis, UroVysion FISH, and cytology as predictors. We
could show that the combination of classic cytology with
LOH analysis (CYTO + LOH) significantly increased the
accuracy to detect malignant urothelial cells in voided
urine (Fig. 2E). In our study, sensitivity and specificity
of conventional cytology was already 88.2% and 79.4%
(AUC = 0.894; Fig. 2A). Using a combination of cytology
and FGFR3 analysis (CYTO + FGFR3), sensitivity and
specificity could not be increased (Fig. 2D). The combina-
tion of cytology with microsatellite analysis (CYTO +
LOH) was able to increase specificity (97.1%) and the area
under the ROC curve (Fig. 2D). However, sensitivity
slightly decreased to 79.4%. Combination of the three
techniques (CYTO + LOH + FGFR3) did not add signifi-
cant diagnostic advantage (Fig. 2F).
These results are contrary to data published by van
Rhijn et al. (28) who have also combined LOH and FGFR3
mutation analysis (molecular grade) for the detection of
urothelial cancer cells in voided urine. After cytologic ex-
amination, an independent set of voided urine samples
was matched with corresponding biopsies and analyzed
for LOH, FGFR3 mutation, polysomy, and p16 deletion
using UroVysion FISH. Combining results of LOH and
FGFR3 mutation analysis, the sensitivity of the combined
approach increased to 89% and was superior to the sensi-
tivity of conventional cytology for every clinical subdivi-
sion (28). In our study, however, sensitivity and specificity
of conventional cytology were already very high (88.2%
and 79.4%). The area under the ROC curve in Fig. 2A
(AUC 0.894) could only be increased by adding the results
of the microsatellite analysis (AUC 0.936; Fig. 2E).
Recently, van der Aa et al. (18) have reported the re-
sults of a longitudinal prospective multicenter trial for
surveillance of patients with low-grade non-muscle-
invasive urothelial cancer using microsatellite analysis
(n = 228). The authors concluded that microsatellite
analysis on voided urine samples is not sufficiently
sensitive to recommend implementation in routine clin-
ical practice.
Classic cytology is still regarded as an important ad-
junct to urethrocystoscopy. Cytologic examination of
voided urine is cheap, established in almost every pathol-
ogy department, and should be part of any bladder can-
cer surveillance protocol. However, application of urine
cytology is operator-dependent and can be hampered
by the low sensitivity for low-grade lesions (29). In con-
trast to our study, simultaneous cytologic examinations
were not taken into account by van der Aa et al. when
calculating sensitivity and specificity of the various tests
(18, 28).
The combination of cytology with LOH analysis
reached the highest diagnostic accuracy for the detection
of urothelial bladder cancer cells in voided urine sam-
ples. A monitoring scheme alternating invasive cys-
toscopy with a combination of noninvasive techniques
(including classic urine cytology and LOH analysis) could
reduce unpleasant interventions and improve follow-up
compliance of patients with recurrent urothelial bladder
cancer.
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